ProCE Banner Activity

VALENTINE-PTCL01: Primary Results of Phase II Trial of Valemetostat Tosylate in Patients With Relapsed/Refractory Peripheral T-Cell Lymphomas

Conference Coverage

Primary results from phase II VALENTINE-PTCL01 trial suggested a high response rate and durable responses with valemetostat tosylate in patients with relapsed or refractory peripheral T-cell lymphomas.

Released: December 11, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.